Clinical Trial Detail

NCT ID NCT02595905
Title Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)
Indications

breast cancer

Therapies

Cisplatin

Cisplatin + Veliparib

Age Groups: senior adult

Additional content available in CKB BOOST